Cargando…
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microva...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394778/ https://www.ncbi.nlm.nih.gov/pubmed/30635728 http://dx.doi.org/10.1007/s00270-018-2150-6 |
_version_ | 1783398967923441664 |
---|---|
author | Titano, Joseph J. Fischman, Aaron M. Cherian, Arnav Tully, Madeline Stein, Lance L. Jacobs, Louis Rubin, Raymond A. Bosley, Michael Citron, Steve Joelson, Dean W. Shrestha, Roshan Arepally, Aravind |
author_facet | Titano, Joseph J. Fischman, Aaron M. Cherian, Arnav Tully, Madeline Stein, Lance L. Jacobs, Louis Rubin, Raymond A. Bosley, Michael Citron, Steve Joelson, Dean W. Shrestha, Roshan Arepally, Aravind |
author_sort | Titano, Joseph J. |
collection | PubMed |
description | INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microvalve infusion catheters offer a means of such improvement. METHODS: All treatment-naive patients with solitary HCC tumors < 6.5 cm who underwent drug-eluting microspheres (DEM) TACE between 04/2015 and 08/2017 were retrospectively reviewed. Eighty-eight included patients underwent DEM-TACE with either standard end-hole catheters (EH) or microvalve infusion catheters (MVI). The EH (n = 70) and MVI (n = 18) cohorts had similar baseline tumor size, laboratory values, and tumor etiologies. RESULTS: Initial objective response rates were significantly higher in MVI vs. EH (100% vs. 76.5%, p = 0.019). There was no difference in adverse events between groups (p = 0.265). MVI patients exhibited lower AST (p = 0.003) and ALT (p = 0.044) at 6 months. Blinded pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in MVI explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). There was significantly higher percentage tumor necrosis in the MVI group (89.0 ± 2.2%) compared with the EH group (56.1 ± 44.5%) (p = 0.006). CONCLUSION: In this retrospective study of a single-center cohort, DEM-TACE procedures with MVI were associated with improved tumor response, increased deposition of microspheres within tumor tissue, and higher percentage tumor necrosis at explant relative to those performed using EH catheters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2150-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6394778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-63947782019-03-15 End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis Titano, Joseph J. Fischman, Aaron M. Cherian, Arnav Tully, Madeline Stein, Lance L. Jacobs, Louis Rubin, Raymond A. Bosley, Michael Citron, Steve Joelson, Dean W. Shrestha, Roshan Arepally, Aravind Cardiovasc Intervent Radiol Clinical Investigation INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microvalve infusion catheters offer a means of such improvement. METHODS: All treatment-naive patients with solitary HCC tumors < 6.5 cm who underwent drug-eluting microspheres (DEM) TACE between 04/2015 and 08/2017 were retrospectively reviewed. Eighty-eight included patients underwent DEM-TACE with either standard end-hole catheters (EH) or microvalve infusion catheters (MVI). The EH (n = 70) and MVI (n = 18) cohorts had similar baseline tumor size, laboratory values, and tumor etiologies. RESULTS: Initial objective response rates were significantly higher in MVI vs. EH (100% vs. 76.5%, p = 0.019). There was no difference in adverse events between groups (p = 0.265). MVI patients exhibited lower AST (p = 0.003) and ALT (p = 0.044) at 6 months. Blinded pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in MVI explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). There was significantly higher percentage tumor necrosis in the MVI group (89.0 ± 2.2%) compared with the EH group (56.1 ± 44.5%) (p = 0.006). CONCLUSION: In this retrospective study of a single-center cohort, DEM-TACE procedures with MVI were associated with improved tumor response, increased deposition of microspheres within tumor tissue, and higher percentage tumor necrosis at explant relative to those performed using EH catheters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2150-6) contains supplementary material, which is available to authorized users. Springer US 2019-01-11 2019 /pmc/articles/PMC6394778/ /pubmed/30635728 http://dx.doi.org/10.1007/s00270-018-2150-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Investigation Titano, Joseph J. Fischman, Aaron M. Cherian, Arnav Tully, Madeline Stein, Lance L. Jacobs, Louis Rubin, Raymond A. Bosley, Michael Citron, Steve Joelson, Dean W. Shrestha, Roshan Arepally, Aravind End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title | End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title_full | End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title_fullStr | End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title_full_unstemmed | End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title_short | End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis |
title_sort | end-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-tace for solitary hepatocellular carcinoma tumors: a retrospective analysis |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394778/ https://www.ncbi.nlm.nih.gov/pubmed/30635728 http://dx.doi.org/10.1007/s00270-018-2150-6 |
work_keys_str_mv | AT titanojosephj endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT fischmanaaronm endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT cherianarnav endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT tullymadeline endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT steinlancel endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT jacobslouis endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT rubinraymonda endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT bosleymichael endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT citronsteve endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT joelsondeanw endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT shrestharoshan endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis AT arepallyaravind endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis |